https://www.selleckchem.com/products/ck-586.html
Weight reductions with dulaglutide were greater in patients with lower versus higher baseline HbA1c. In patients with T2D, inadequately controlled by metformin, incremental weight loss was observed with dulaglutide 1.5, 3.0 and 4.5mg doses regardless of baseline BMI or HbA1c. Although absolute weight loss was numerically greater in patients with higher baseline BMI, percentage of weight loss was similar between BMI subgroups. In patients with T2D, inadequately controlled by metformin, incremental weight loss was observed with dulaglutide
Like
Comment
Share
